The cuffless technology, which has already gained CE mark approval, should make its U.S. debut in 2026. The cuffless technology, which has already gained CE mark approval, should make its U.S. debut in 2026. | | |
|
Care teams should be aware of this difference, even using CT images when possible to look for signs of any potential issues. Care teams should be aware of this difference, even using CT images when possible to look for signs of any potential issues. | | |
|
Statins appear to be the most impactful for patients diagnosed with hypertension or cerebrovascular disease. Statins appear to be the most impactful for patients diagnosed with hypertension or cerebrovascular disease. | | |
|
|
The new drug, LX2006, has already received the FDA's fast track designation. This latest distinction was based on early data from two separate clinical trials. The new drug, LX2006, has already received the FDA's fast track designation. This latest distinction was based on early data from two separate clinical trials. | | |
|
The Heart Rhythm Society and its new advocacy arm plan on pushing CMS to include certain policy improvements in the 2026 MPFS. The Heart Rhythm Society and its new advocacy arm plan on pushing CMS to include certain policy improvements in the 2026 MPFS. | | |
|
When doctors are accused of mishandling the heart health of a young athlete, it occasionally ends up being settled in a courtroom. When doctors are accused of mishandling the heart health of a young athlete, it occasionally ends up being settled in a courtroom. | | |
|
|
The news is related to an earlier recall of more than 316,000 Medtronic devices. The news is related to an earlier recall of more than 316,000 Medtronic devices. | | |
|
After being ordered to pay $442 million in damages—a ruling the company has said it may appeal—Johnson & Johnson MedTech is now facing the possibility of a permanent injunction that could impact certain business practices. A hearing is scheduled for July. After being ordered to pay $442 million in damages—a ruling the company has said it may appeal—Johnson & Johnson MedTech is now facing the possibility of a permanent injunction that could impact certain business practices. A hearing is scheduled for July. | | |
|
The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions. The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions. | | |
|
|
“Patients should have the freedom to choose the highest quality care available, and physicians should be allowed to provide it,” said Rep. Beth Van Duyne, R-Texas. “Patients should have the freedom to choose the highest quality care available, and physicians should be allowed to provide it,” said Rep. Beth Van Duyne, R-Texas. | | |
|
New research suggests the technique can effectively break down amyloid fibrinogen microclots, which are believed to interfere with perfusion and cause inflammation. New research suggests the technique can effectively break down amyloid fibrinogen microclots, which are believed to interfere with perfusion and cause inflammation. | | |
|
|
| |
| Biome Analytics has launched Biome IMPACT, a new AI-enabled methodology to support cardiovascular performance improvement. The framework helps health systems identify opportunities, align stakeholders and track measurable results—without adding to the team’s workload. READ MORE > |
|
|
|
| |
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](https://cardiovascularbusiness.com/sites/default/files/styles/media_thumbnail/public/2024-09/istock-1209664264.jpg?itok=d9hdApI9)
